Citi analyst Daniel Grosslight lowered the firm’s price target on Evolent Health (EVH) to $21 from $33 and keeps a Buy rating on the shares. The analyst updated health technology models post the Q3 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH: